MX2021003606A - Compuestos de bifenil-sulfonamida para el tratamiento de enfermedades de colageno tipo iv. - Google Patents
Compuestos de bifenil-sulfonamida para el tratamiento de enfermedades de colageno tipo iv.Info
- Publication number
- MX2021003606A MX2021003606A MX2021003606A MX2021003606A MX2021003606A MX 2021003606 A MX2021003606 A MX 2021003606A MX 2021003606 A MX2021003606 A MX 2021003606A MX 2021003606 A MX2021003606 A MX 2021003606A MX 2021003606 A MX2021003606 A MX 2021003606A
- Authority
- MX
- Mexico
- Prior art keywords
- type
- biphenyl
- treatment
- sulfonamide compounds
- collagen diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Urology & Nephrology (AREA)
- Physiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862741270P | 2018-10-04 | 2018-10-04 | |
| US201962853904P | 2019-05-29 | 2019-05-29 | |
| US201962894559P | 2019-08-30 | 2019-08-30 | |
| PCT/US2019/054559 WO2020072814A1 (en) | 2018-10-04 | 2019-10-03 | Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021003606A true MX2021003606A (es) | 2021-08-16 |
Family
ID=68318947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021003606A MX2021003606A (es) | 2018-10-04 | 2019-10-03 | Compuestos de bifenil-sulfonamida para el tratamiento de enfermedades de colageno tipo iv. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11207299B2 (https=) |
| EP (1) | EP3860594B1 (https=) |
| JP (2) | JP7524167B2 (https=) |
| KR (1) | KR102902972B1 (https=) |
| CN (1) | CN113286587A (https=) |
| AU (1) | AU2019354784B2 (https=) |
| BR (1) | BR112021006132A2 (https=) |
| CA (1) | CA3114434A1 (https=) |
| ES (1) | ES3057657T3 (https=) |
| IL (1) | IL281965B1 (https=) |
| MA (1) | MA53817A (https=) |
| MX (1) | MX2021003606A (https=) |
| WO (1) | WO2020072814A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117017985A (zh) | 2016-10-13 | 2023-11-10 | 特拉维尔治疗公司 | 用于治疗肾脏疾病或病症的联苯磺酰胺化合物 |
| WO2022246200A1 (en) * | 2021-05-21 | 2022-11-24 | Travere Therapeutics, Inc. | Methods of treating kidney diseases or disorders |
| WO2022266370A1 (en) * | 2021-06-17 | 2022-12-22 | Aria Pharmaceuticals, Inc. | Sparsentan for treating idiopathic pulmonary fibrosis |
| JP2025183466A (ja) * | 2022-11-11 | 2025-12-17 | 株式会社アークメディスン | 化合物、エンドセリンａ受容体拮抗剤、アンジオテンシンｉｉタイプ１受容体拮抗剤及び医薬組成物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6638937B2 (en) | 1998-07-06 | 2003-10-28 | Bristol-Myers Squibb Co. | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| HUP0104634A3 (en) | 1998-07-06 | 2002-11-28 | Bristol Myers Squibb Co | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| ATE339417T1 (de) | 1999-12-15 | 2006-10-15 | Bristol Myers Squibb Co | Biphenyl - sulfonamide als duale angiotensin - endothelin - rezeptor - antagonisten |
| WO2010114801A1 (en) | 2009-03-31 | 2010-10-07 | Ligand Pharmaceuticals Inc. | Oral formulations of diphenylsulfonamide endothelin and angiotensin ii receptor agonists to treat elevated blood pressure and diabetic nephropathy |
| WO2010135350A2 (en) | 2009-05-20 | 2010-11-25 | Pharmacopeia, Llc | Biphenyl intermediate compounds and methods for the preparation of a dual angiotensin ii and endothelin a receptor antagonist |
| US9719981B2 (en) | 2012-08-17 | 2017-08-01 | Father Flanagan's Boys' Home | RAC1 inhibitors for the treatment of alport glomerular disease |
| CA2958585C (en) * | 2014-08-21 | 2024-01-09 | Stealth Biotherapeutics Corp | Use of peptide d-arg-2',6'-dmt-lys-phe-nh2 for the treatment of alport syndrome |
| EP3515501A1 (en) * | 2016-09-19 | 2019-07-31 | Aten Porus Lifesciences | Cyclodextrin based polymers, methods, compositions and applications thereof |
| CN117017985A (zh) * | 2016-10-13 | 2023-11-10 | 特拉维尔治疗公司 | 用于治疗肾脏疾病或病症的联苯磺酰胺化合物 |
| US20220048900A1 (en) | 2018-12-21 | 2022-02-17 | Travere Therapuetics, Inc. | Amorphous sparsentan compositions |
-
2019
- 2019-10-03 MA MA053817A patent/MA53817A/fr unknown
- 2019-10-03 BR BR112021006132-0A patent/BR112021006132A2/pt unknown
- 2019-10-03 EP EP19791401.3A patent/EP3860594B1/en active Active
- 2019-10-03 IL IL281965A patent/IL281965B1/en unknown
- 2019-10-03 JP JP2021518888A patent/JP7524167B2/ja active Active
- 2019-10-03 MX MX2021003606A patent/MX2021003606A/es unknown
- 2019-10-03 WO PCT/US2019/054559 patent/WO2020072814A1/en not_active Ceased
- 2019-10-03 AU AU2019354784A patent/AU2019354784B2/en active Active
- 2019-10-03 US US16/592,633 patent/US11207299B2/en active Active
- 2019-10-03 CN CN201980079773.4A patent/CN113286587A/zh active Pending
- 2019-10-03 KR KR1020217010358A patent/KR102902972B1/ko active Active
- 2019-10-03 ES ES19791401T patent/ES3057657T3/es active Active
- 2019-10-03 CA CA3114434A patent/CA3114434A1/en active Pending
-
2024
- 2024-07-17 JP JP2024114026A patent/JP2024133735A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7524167B2 (ja) | 2024-07-29 |
| BR112021006132A2 (pt) | 2021-07-20 |
| US20200147050A1 (en) | 2020-05-14 |
| JP2024133735A (ja) | 2024-10-02 |
| MA53817A (fr) | 2021-08-11 |
| CN113286587A (zh) | 2021-08-20 |
| EP3860594B1 (en) | 2025-10-01 |
| CA3114434A1 (en) | 2020-04-09 |
| AU2019354784A1 (en) | 2021-04-15 |
| IL281965A (en) | 2021-05-31 |
| WO2020072814A1 (en) | 2020-04-09 |
| JP2022514152A (ja) | 2022-02-10 |
| AU2019354784B2 (en) | 2025-07-10 |
| IL281965B1 (en) | 2026-04-01 |
| US11207299B2 (en) | 2021-12-28 |
| ES3057657T3 (en) | 2026-03-03 |
| KR20210081338A (ko) | 2021-07-01 |
| KR102902972B1 (ko) | 2025-12-22 |
| EP3860594A1 (en) | 2021-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019015090A2 (es) | Métodos de tratamiento para la fibrosis cística | |
| DOP2023000251A (es) | Compuestos oligoméricos que inhiben la expresión de hsd17b13 | |
| MX2021003606A (es) | Compuestos de bifenil-sulfonamida para el tratamiento de enfermedades de colageno tipo iv. | |
| MX2022000143A (es) | Metodos novedosos. | |
| AR107871A1 (es) | Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos | |
| UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
| UY37182A (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| MX2014002171A (es) | Tratamientos de combinacion para hepatitis c. | |
| UY37742A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| CR20180253A (es) | Composiciones terapéuticas para el tratamiento del virus de unmunodeficiencia humana | |
| CL2021000030A1 (es) | Uso de estimuladores de la sgc para el tratamiento de trastornos mitocondriales | |
| MX2020010697A (es) | Kit, composicion y terapia de combinacion para el sindrome del cromosoma x fragil. | |
| DOP2016000254A (es) | Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso. | |
| CO2022005999A2 (es) | Inhibidores del factor d del complemento para administración oral | |
| AR103415A1 (es) | Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2 | |
| MX2021008432A (es) | Composiciones farmaceuticas y usos dirigidos a los trastornos del almacenamiento lisosomal. | |
| MX2018008903A (es) | COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA. | |
| ECSP22036455A (es) | Inhibidores del factor d del complemento para administraci?n oral | |
| MX2016011115A (es) | Terapia inmunorreguladora contra autoinmunidad en diabetes tipo 1. | |
| CL2021002107A1 (es) | Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria. | |
| CO2023017669A2 (es) | Terapia combinada anti-vhc ventajosa | |
| PY1944026A (es) | Ácido ascórbico y compuestos quinona en combinación con un agente antiparasitario para tratar enfermedades parasitarias | |
| PE20181450A1 (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer | |
| MX2021014523A (es) | Metodos para tratar colangiocarcinoma. | |
| MX2022002838A (es) | Compuesto heterocíclico aromático que tiene estructura tricíclica, y método de preparación y aplicación del mismo. |